187 related articles for article (PubMed ID: 17583416)
41. A prospective comparison of prostate cancer at autopsy and as a clinical event: the Hawaii Japanese experience.
Stemmermann GN; Nomura AM; Chyou PH; Yatani R
Cancer Epidemiol Biomarkers Prev; 1992; 1(3):189-93. PubMed ID: 1306104
[TBL] [Abstract][Full Text] [Related]
42. Active surveillance for the management of prostate cancer in a contemporary cohort.
Dall'Era MA; Konety BR; Cowan JE; Shinohara K; Stauf F; Cooperberg MR; Meng MV; Kane CJ; Perez N; Master VA; Carroll PR
Cancer; 2008 Jun; 112(12):2664-70. PubMed ID: 18433013
[TBL] [Abstract][Full Text] [Related]
43. Long-term outcome of hematuria home screening for bladder cancer in men.
Messing EM; Madeb R; Young T; Gilchrist KW; Bram L; Greenberg EB; Wegenke JD; Stephenson L; Gee J; Feng C
Cancer; 2006 Nov; 107(9):2173-9. PubMed ID: 17029275
[TBL] [Abstract][Full Text] [Related]
44. Characteristics of prostate cancer detected by digital rectal examination only.
Okotie OT; Roehl KA; Han M; Loeb S; Gashti SN; Catalona WJ
Urology; 2007 Dec; 70(6):1117-20. PubMed ID: 18158030
[TBL] [Abstract][Full Text] [Related]
45. Comparison of prostate specific antigen velocity in screened versus referred patients with prostate cancer.
Meeks JJ; Thaxton CS; Loeb S; Roehl KA; Helfand BT; Catalona WJ
J Urol; 2008 Apr; 179(4):1340-3. PubMed ID: 18289590
[TBL] [Abstract][Full Text] [Related]
46. A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices.
Howard K; Barratt A; Mann GJ; Patel MI
Arch Intern Med; 2009 Sep; 169(17):1603-10. PubMed ID: 19786680
[TBL] [Abstract][Full Text] [Related]
47. Mass screening-based case-control study of diet and prostate cancer in Changchun, China.
Li XM; Li J; Tsuji I; Nakaya N; Nishino Y; Zhao XJ
Asian J Androl; 2008 Jul; 10(4):551-60. PubMed ID: 18478158
[TBL] [Abstract][Full Text] [Related]
48. Over-diagnosis and under-diagnosis of screen- vs non-screen-detected prostate cancers with in men with prostate-specific antigen levels of 2.0-10.0 ng/mL.
Pelzer AE; Colleselli D; Bektic J; Schaefer G; Ongarello S; Schwentner C; Aigner F; Mitterberger M; Steiner E; Bartsch G; Horninger W
BJU Int; 2008 May; 101(10):1223-6. PubMed ID: 18190631
[TBL] [Abstract][Full Text] [Related]
49. Prostate-specific antigen kinetics in screen-detected prostate cancer in Japan.
Takechi H; Ito K; Yamamoto T; Miyakubo M; Ohi M; Suzuki K
Urology; 2008 Nov; 72(5):1111-5. PubMed ID: 18342926
[TBL] [Abstract][Full Text] [Related]
50. Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam.
van der Cruijsen-Koeter IW; Roobol MJ; Wildhagen MF; van der Kwast TH; Kirkels WJ; Schröder FH
Urology; 2006 Sep; 68(3):615-20. PubMed ID: 17010732
[TBL] [Abstract][Full Text] [Related]
51. Ten year trend in prostate cancer screening with high prostate-specific antigen exposure rate in Japan.
Okihara K; Kitamura K; Okada K; Mikami K; Ukimura O; Miki T
Int J Urol; 2008 Feb; 15(2):156-60; discussion 161. PubMed ID: 18269453
[TBL] [Abstract][Full Text] [Related]
52. Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era.
Ercole B; Marietti SR; Fine J; Albertsen PC
J Urol; 2008 Oct; 180(4):1336-9; discussion 1340-1. PubMed ID: 18707696
[TBL] [Abstract][Full Text] [Related]
53. Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.
Sun L; Caire AA; Robertson CN; George DJ; Polascik TJ; Maloney KE; Walther PJ; Stackhouse DA; Lack BD; Albala DM; Moul JW
J Urol; 2009 Nov; 182(5):2242-8. PubMed ID: 19758616
[TBL] [Abstract][Full Text] [Related]
54. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
[TBL] [Abstract][Full Text] [Related]
55. The Japanese guideline for prostate cancer screening.
Hamashima C; Nakayama T; Sagawa M; Saito H; Sobue T
Jpn J Clin Oncol; 2009 Jun; 39(6):339-51. PubMed ID: 19346535
[TBL] [Abstract][Full Text] [Related]
56. Screening for prostate cancer (PC)--an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH
Urol Oncol; 2008; 26(5):533-41. PubMed ID: 18774469
[TBL] [Abstract][Full Text] [Related]
57. Clinical outcome of Taiwanese men with metastatic prostate cancer compared with other ethnic groups.
Chen CH; Tzai TS; Huang SP; Wu HC; Tai HC; Chang YH; Pu YS
Urology; 2008 Dec; 72(6):1287-92. PubMed ID: 18372020
[TBL] [Abstract][Full Text] [Related]
58. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
[TBL] [Abstract][Full Text] [Related]
59. Place of residence effect on likelihood of surviving prostate cancer.
Gregorio DI; Huang L; DeChello LM; Samociuk H; Kulldorff M
Ann Epidemiol; 2007 Jul; 17(7):520-4. PubMed ID: 17448679
[TBL] [Abstract][Full Text] [Related]
60. Association of colorectal cancer and prostate cancer and impact of radiation therapy.
Huo D; Hetzel JT; Roy H; Rubin DT
Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):1979-85. PubMed ID: 19531678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
